의료 문서 작성용 AI 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

AI In Medical Writing Market Growth & Trends:

The global AI in medical writing market size is anticipated to reach USD 1,760.02 million by 2030, registering a CAGR of 12.52% from 2025 to 2030, according to a new report by Grand View Research, Inc. The primary factor driving the market expansion is the growing acceptance of machine learning, such as Artificial Intelligence(AI), in the healthcare industry. Moreover, the rising demand for reducing healthcare expenditures and increasing R&D investments by pharmaceutical companies to reduce expenses are other factors that are propelling market growth. The COVID-19 pandemic had affected the market moderately. The pandemic caused a pause in research and development activities as well as clinical trials.

Moreover, budgetary limitations led many pharmaceutical companies to reduce their investments. The initial stages of the pandemic also resulted in a decrease in submissions to healthcare journals, negatively impacting market growth. However, the significance of collaborative efforts between companies, research groups, and government bodies in the development of innovative therapies was demonstrated during the COVID-19 pandemic. Consequently, medical device, biotechnology, and life science companies have intentions to boost their investment in medical writers. Thus, increasing the demand for AI in the healthcare industry during the COVID-19 pandemic.

AI In Medical Writing Market Report Highlights:

• Based on type, the typewriting segment dominated the market with a share of 32.89% of the overall revenue in 2024 due to the necessity of submitting regulatory documents to the authorities. Thus, boosting the demand for AI in medical writing in this segment
• Based on end-use, the pharmaceutical segment dominated the market with a revenue share of 33.33% in 2024.
• The high share was attributed to the heavy investments in R&D activities to develop new drugs and treatments, which augmented the demand for AI in medical writing in this end-use segment
• In 2024, North America dominated the market with a revenue share of 30.12% owing to the continuous technological advancements, increasing healthcare infrastructure, and a high number of drug trials & their approvals

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. End Use
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. End use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. AI in Medical Writing Market Variables, Trends & Scope

• 3.1. Market Dynamics
  • 3.1.1. Market driver analysis
  • 3.1.2. Market restraint analysis
  • 3.1.3. Market Opportunities
• 3.2. AI in Medical Writing Market Analysis Tools
  • 3.2.1. Industry Analysis - Porter's
    • 3.2.1.1. Supplier power
    • 3.2.1.2. Buyer power
    • 3.2.1.3. Substitution threat
    • 3.2.1.4. Threat of new entrant
    • 3.2.1.5. Competitive rivalry
  • 3.2.2. PESTEL Analysis
    • 3.2.2.1. Political landscape
    • 3.2.2.2. Economic landscape
    • 3.2.2.3. Social landscape
    • 3.2.2.4. Technological landscape
    • 3.2.2.5. Environmental landscape
    • 3.2.2.6. Legal landscape
  • 3.2.3. COVID-19 Impact Analysis
  • 3.2.4. Case Studies

Chapter 4. AI in Medical Writing Market: Type Estimates & Trend Analysis

• 4.1. Type Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global AI in Medical Writing Market by Product Type Outlook
• 4.4. Clinical Writing
  • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.5. Scientific Writing
  • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.6. Type Writing
  • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. AI in Medical Writing Market: End Use Estimates & Trend Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global AI in Medical Writing Market by End Use Outlook
• 5.4. Medical Devices
  • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.5. Pharmaceutical
  • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.6. Biotechnology
  • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. AI in Medical Writing Market: Regional Estimates & Trend Analysis, By Product, By Type, By End Use

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Mexico
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Norway
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/ reimbursement structure
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.8. Denmark
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/ reimbursement structure
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/ reimbursement structure
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Argentina
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework/ reimbursement structure
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/ reimbursement structure
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/ reimbursement structure
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/ reimbursement structure
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Key company market share/position analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. Parexel International (MA) Corporation.
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Technology Type benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Trilogy Writing & Consulting GmbH
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Technology Type benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Freyr
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Technology Type benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Cactus Communications
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Technology Type benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. GENINVO
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Technology Type benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. IQVIA Inc.
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Technology Type benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. ICON plc
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Technology Type benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Syneos Health
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Technology Type benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. IBM
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Technology Type benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Teladoc Health, Inc.
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Technology Type benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. SmarterDx
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Technology Type benchmarking
    • 7.4.11.4. Strategic initiatives
  • 7.4.12. Abridge Al, Inc.
    • 7.4.12.1. Company overview
    • 7.4.12.2. Financial performance
    • 7.4.12.3. Technology Type benchmarking
    • 7.4.12.4. Strategic initiatives
  • 7.4.13. Suki AI, Inc.
    • 7.4.13.1. Company overview
    • 7.4.13.2. Financial performance
    • 7.4.13.3. Technology Type benchmarking
    • 7.4.13.4. Strategic initiatives
  • 7.4.14. Movano
    • 7.4.14.1. Company overview
    • 7.4.14.2. Financial performance
    • 7.4.14.3. Technology Type benchmarking
    • 7.4.14.4. Strategic initiatives
  • 7.4.15. Heidi
    • 7.4.15.1. Company overview
    • 7.4.15.2. Financial performance
    • 7.4.15.3. Technology Type benchmarking
    • 7.4.15.4. Strategic initiatives
  • 7.4.16. Corti
    • 7.4.16.1. Company overview
    • 7.4.16.2. Financial performance
    • 7.4.16.3. Technology Type benchmarking
    • 7.4.16.4. Strategic initiatives
  • 7.4.17. Tortus AI.
    • 7.4.17.1. Company overview
    • 7.4.17.2. Financial performance
    • 7.4.17.3. Technology Type benchmarking
    • 7.4.17.4. Strategic initiatives
  • 7.4.18. Nabla Technologies
    • 7.4.18.1. Company overview
    • 7.4.18.2. Financial performance
    • 7.4.18.3. Technology Type benchmarking
    • 7.4.18.4. Strategic initiatives